Handelsavisen
prelaunch
Companies ›000411.SZ
00
000411.SZ — Shenzhen Stock Exchange Unclassified

Zhejiang Int'l Group Co Ltd

¥12,11
Open in Charts → Attach watcher ⌖
— —
CNY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
6,8B CNY
P/E
—
EV / Rev
—
Div yield
3,77 %
Op margin
2,5 %
ROE
9,8 %
Net margin
1,5 %
Debt / equity
0,82
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Zhejiang Int'l Group Co Ltd operates in the Health Care sector, specifically within Pharmaceuticals, generating revenue through its disclosed business activities.

Business. Zhejiang Int'l Group Co Ltd operates in the Health Care sector, specifically within Pharmaceuticals, generating revenue through its disclosed business activities.

Classification20 %
SectorUnclassified
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
9,8 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 000411.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 000411.SZ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Zhejiang Int'l Group Co Ltd operates in the Health Care sector, specifically within Pharmaceuticals, generating revenue through its disclosed business activities.

    Classification20 %
    SectorUnclassified
    AI synthesis
    GENERATED
    — missing data
    Key takeaways
    • The company trades at a low EV/Revenue multiple of 0.28, suggesting potential undervaluation relative to sales scale.
    • Leverage is moderate with a debt-to-equity ratio of 0.82, but net cash is negative, indicating reliance on debt financing.
    • Profitability is modest with a 9.82% ROE and 2.99% ROA, driven by a 7.0% gross margin on 33.68 billion CNY in revenue.
    • Dilution risk is low, with no difference between basic and diluted shares outstanding.
    • Liquidity risk is rated medium, supported by a current ratio of 1.36.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    ¥12,11
    Market cap
    ¥5.30B
    Enterprise valueⓘ
    ¥9.47B
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    26.6x
    P / Bⓘ
    1.0x
    P / Tangible bookⓘ
    1.0x
    Tangible book
    ¥5.10B
    Net cashⓘ
    -¥4.17B
    Current ratioⓘ
    1.4
    Debt / equityⓘ
    0.8
    ROAⓘ
    3.0%
    ROEⓘ
    9.8%
    Cash conversionⓘ
    71.0%
    CapEx / revenueⓘ
    -0.7%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Active Pharmaceutical Ingredients (API)—
    low · llm_fanout_v2
    Branded / Innovative Medicines—
    low · llm_fanout_v2

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin2,5 %Below median
    Net Margin1,5 %Below median
    ROE9,8 %Above median
    Capex / Rev-0,7 %Above P75
    D/E0,82Below median
    Cash Conv0,71Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    • Reference data
    How metrics are computed
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Price To Tangible Book
      market_price / (tangible_book_value / shares_outstanding_diluted)
    • Ev To Operating Income
      enterprise_value / operating_income
    Source documents
    • Zhejiang Int'l Group Co Ltd Market data — financials · 2026-07-08

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    000411.SZCanonical
    Shenzhen Stock Exchange · CNY

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2017-04-21 19:10 UTCEARNINGSAnnual results — FY 2017 Revenue CNY 32.05B · Net CNY 488.7M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage